Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors originating from neuroendocrine cells dispersed in different organs. Receptor tyrosine kinases are a subclass of tyrosine kinases with a relevant role in several cellular processes including proliferation, differentiation, motility and metabolism. Dysregulation of these receptors is involved in neoplastic development and progression for several tumors, including NENs. In this review, we provide an overview concerning the role of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) system in the development and progression of NENs, the occurrence of fibrotic complications and the onset of drug-resistance. Although no specific FGFR kinase inhibitors have been evaluated in NENs, several clinical trials on multitarget tyrosine kinase inhibitors, acting also on FGF system, showed promising anti-tumor activity with an acceptable and manageable safety profile in patients with advanced NENs. Future studies will need to confirm these issues, particularly with the development of new tyrosine kinase inhibitors highly selective for FGFR.

Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications / G. Vitale, A. Cozzolino, P. Malandrino, R. Minotta, G. Puliani, D. Saronni, A. Faggiano, A. Colao. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - 12(2021 Apr 14), pp. 665631.1-665631.9. [10.3389/fendo.2021.665631]

Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications

G. Vitale
Primo
;
D. Saronni;
2021

Abstract

Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors originating from neuroendocrine cells dispersed in different organs. Receptor tyrosine kinases are a subclass of tyrosine kinases with a relevant role in several cellular processes including proliferation, differentiation, motility and metabolism. Dysregulation of these receptors is involved in neoplastic development and progression for several tumors, including NENs. In this review, we provide an overview concerning the role of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) system in the development and progression of NENs, the occurrence of fibrotic complications and the onset of drug-resistance. Although no specific FGFR kinase inhibitors have been evaluated in NENs, several clinical trials on multitarget tyrosine kinase inhibitors, acting also on FGF system, showed promising anti-tumor activity with an acceptable and manageable safety profile in patients with advanced NENs. Future studies will need to confirm these issues, particularly with the development of new tyrosine kinase inhibitors highly selective for FGFR.
FGF (fibroblast growth factor); FGFR (fibroblast growth factor receptor); neuroendocrine neoplasms; VEGF - vascular endothelial growth factor; VEGFR - vascular endothelial growth factor receptor
Settore MED/13 - Endocrinologia
Settore MED/09 - Medicina Interna
   From bed to benchside: untAngling THe molecular mechanisms of disease progressioN in neuroenDocRine nEoplAsMS (FAITH IN DREAMS)
   FAITH IN DREAMS
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2017Z3N3YC_003
14-apr-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
153.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 352.1 kB
Formato Adobe PDF
352.1 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/849966
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact